SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Life Scienc - Quaterly Results

21 Oct 2022 Evaluate
The sales is pegged at Rs. 5092.99 millions for the September 2022 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 5617.61 millions during the year-ago period.A slender decline of -7.22% was recorded to Rs. 1068.78  millions from Rs. 1152.01 millions in the corresponding previous quarter.Operating Profit reported a sharp decline to 1536.59 millions from 1694.26 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 5092.99 5617.61 -9.34 9991.69 10866.58 -8.05 21232.14 18851.65 12.63
Other Income 100.20 20.89 379.66 195.13 60.75 221.20 147.04 8.11 1713.07
PBIDT 1536.59 1694.26 -9.31 3099.20 3338.60 -7.17 6307.64 5918.85 6.57
Interest 1.33 72.26 -98.16 2.68 277.76 -99.04 279.62 875.47 -68.06
PBDT 1535.26 1622.00 -5.35 3096.52 3060.84 1.17 6028.02 5043.38 19.52
Depreciation 99.35 96.65 2.79 198.14 185.84 6.62 378.77 333.94 13.42
PBT 1435.91 1525.35 -5.86 2898.38 2875.00 0.81 5649.25 4709.44 19.96
TAX 367.13 373.34 -1.66 742.27 713.86 3.98 1462.01 1193.63 22.48
Deferred Tax 28.20 7.91 256.51 41.05 26.00 57.88 85.74 66.17 29.58
PAT 1068.78 1152.01 -7.22 2156.11 2161.14 -0.23 4187.24 3515.81 19.10
Equity 245.05 245.05 0.00 245.05 245.05 0.00 245.05 19.60 1150.26
PBIDTM(%) 30.17 30.16 0.04 31.02 30.72 0.96 29.71 31.40 -5.38

Alivus Life Sciences Share Price

1062.55 -4.10 (-0.38%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×